OUD

CE / CME

Module 6: Opioid Use Disorder

Physician Assistants/Physician Associates: 1.00 AAPA Category 1 CME credit

Nurses: 1.00 Nursing contact hour

ABIM MOC: maximum of 1.00 Medical Knowledge MOC point

Optometrists: 1.00 COPE CE credit 

ABP MOC: maximum of 1.00 MOC point

ABS MOC: maximum of 1.00 Continuous Certification credit

ABOHNS MOC: maximum of 1.00 Part II Self-Assessment Credit

ABPath MOC: maximum of 1.00 Lifelong Learning point

Dental Professionals: 1.00 ADA CERP credit

Physicians: maximum of 1.00 AMA PRA Category 1 Credit

Released: May 31, 2023

Expiration: May 30, 2026

Timothy Atkinson
Timothy Atkinson, PharmD, BCPS, CPE

Activity

Progress
1 2 3
Course Completed

References

Policy Syst. 2020;18:87.
20.    Madras BK, Ahmad NJ, Wen J, et al. Improving access to evidence-based medical treatment for opioid use disorder: strategies to address key barriers within the treatment system. NAM Perspect. 2020;10:31478 /202004b.
21.    National Academies of Sciences. Barriers to broader use of medications to treat opioid use disorder. ncbi.nlm.nih.gov/books/NBK541389/. Accessed May 21, 2023.
22.    Patel K, Bunachita S, Agarwal AA, et al. Opioid use disorder: treatments and barriers. Cureus. 2021;13:e13173.
23.    National Institute on Drug Abuse. Screening and assessment tools chart. nida.nih.gov/nidamed-medical-health-professionals/screening-tools-resources/chart-screening-tools. Accessed May 21, 2023.
24.    McNeely J, Wu L-T, Subramanian G. Performance of the tobacco, alcohol, prescription medication, and other substance use (TAPS) tool for substance use screening in primary care patients. Ann Intern Med. 2016:165:690-699.
25.    National Institutes of Health. TAPS: Tobacco, Alcohol, Prescription medication, and other Substance use Tool. nida.nih.gov/taps2/#/. Accessed May 21, 2023.
26.    Stiggelbout AM, Pieterse AH, De Haes JCJM. Shared decision making: concepts, evidence, and practice. Patient Educ Couns. 2015;98:1172-1179.
27.    Atkinson TJ, Pisansky AJB, Miller KL, et al. Common elements in opioid use disorder guidelines for buprenorphine prescribing. Am J Manag Care. 2019;25:e88-e97.
28.    Mark TL, Hinde JM, Zarkin GA. Adherence to buprenorphine treatment guidelines among individuals with an opioid use disorder who have private insurance. J Subst Abuse Treat. 2020;116:108062.
29.    Haffajee RL, Bohnert ASB, Lagisetty PA. Policy pathways to address provider workforce barriers to buprenorphine treatment. Am J Prev Med. 2018;54:S230-S242.
30.    Atkinson TJ, Fudin J, Pandula A, et al. Medication pain management in the elderly: unique and underutilized analgesic treatment options. Clin Ther. 2013;35:1669-1689.
31.    Substance Abuse and Mental Health Services Administration. Medications, counseling, and related conditions: medications for substance abuse disorders. samhsa.gov/medications-substance-use-disorders/medications-counseling-related-conditions. Accessed May 21, 2023.
32.    Substance Abuse and Mental Health Services Administration. Opioid treatment providers resources and information. samhsa.gov/medications-substance-use-disorders/otp-resources. Accessed May 21, 2023.
33.    Indian Health Service. Office based opioid treatment (OBOT). ihs.gov/opioids/recovery/obot/. Accessed May 21, 2023.
34.    Boas RA, Villiger JW. Clinical actions of fentanyl and buprenorphine. The significance of receptor binding. Br J Anaesth. 1985;57:192-196.
35.    Evans HC, Easthope SE. Transdermal buprenorphine. Drugs. 2003;63:1999-2010.
36.    Greenwald MK, Johanson C-E, Moody DE, et al. Effects of buprenorphine maintenance dose on mu-opioid receptor availability, plasma concentrations, and antagonist blockade in heroin-dependent volunteers. Neuropsychopharmacology. 2003;28:2000-2009.
37.    Buprenorphine [prescribing information]. Columbus, OH: Roxane Laboratories, Inc; 2015.
38.    Buprenorphine and naloxone [prescribing information]. Warren, NJ: Aquestive Therapeutics; 2023.
39.    Gossop M, Stewart D, Marsden J. Attendance at Narcotics Anonymous and Alcoholics Anonymous meetings, frequency of attendance and substance use outcomes after residential treatment for drug dependence: a 5-year follow-up study. Addiction. 2008;103:119-125.
40.    Carmichael A-N, Morgan L, Del Fabbro E. Identifying and assessing the risk for opioid abuse in patients with cancer: an integrative review. Subst Abuse Rehabil. 2016;7:71-79.
41.    Han B, Compton WM, Blanco C, et al. Prescription opioid use, misuse, and use disorders in U.S. adults: 2015 national survey on drug use and health. Ann Intern Med. 2017;167:293-301.
42.    Paice JA, Portenoy R, Lacchetti C, et al. Management of chronic pain in survivors of adult cancers: American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncology. 2016;34:3325-3345.